JP2005232085A - Active oxygen-reducing agent - Google Patents
Active oxygen-reducing agent Download PDFInfo
- Publication number
- JP2005232085A JP2005232085A JP2004043523A JP2004043523A JP2005232085A JP 2005232085 A JP2005232085 A JP 2005232085A JP 2004043523 A JP2004043523 A JP 2004043523A JP 2004043523 A JP2004043523 A JP 2004043523A JP 2005232085 A JP2005232085 A JP 2005232085A
- Authority
- JP
- Japan
- Prior art keywords
- active oxygen
- lactalbumin
- reducing agent
- reducing
- action
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003638 chemical reducing agent Substances 0.000 title claims abstract description 8
- 102000004407 Lactalbumin Human genes 0.000 claims abstract description 24
- 108090000942 Lactalbumin Proteins 0.000 claims abstract description 24
- 235000021241 α-lactalbumin Nutrition 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 11
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 24
- 239000001301 oxygen Substances 0.000 claims description 24
- 229910052760 oxygen Inorganic materials 0.000 claims description 24
- 230000001603 reducing effect Effects 0.000 claims description 10
- 230000000694 effects Effects 0.000 abstract description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 235000013305 food Nutrition 0.000 description 9
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 8
- 235000013336 milk Nutrition 0.000 description 8
- 239000008267 milk Substances 0.000 description 8
- 210000004080 milk Anatomy 0.000 description 8
- 102000016938 Catalase Human genes 0.000 description 6
- 108010053835 Catalase Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 201000008383 nephritis Diseases 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- -1 lipid peroxide Chemical class 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 230000003796 beauty Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 206010016326 Feeling cold Diseases 0.000 description 2
- 206010019133 Hangover Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010040954 Skin wrinkling Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 235000019750 Crude protein Nutrition 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000000254 damaging effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 210000000585 glomerular basement membrane Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
本発明は、α−ラクトアルブミンを有効成分とする活性酸素低減剤に関する。更に詳しくは、本発明は、活性酸素が原因となる各種の病気、例えば、血流障害による病気（心筋梗塞、脳卒中、高血圧、生理痛、肩こり、神経痛、腰痛、二日酔い等）、成人病・内科疾患（癌、腎炎、肝炎、糖尿病等）、美容・皮膚病（しみ、そばかす、肌荒れ、冷え症、便秘、しわ、アトピー性皮膚炎等）等の治療、改善等に広く利用され得る活性酸素低減剤に関する。 The present invention relates to an active oxygen reducing agent containing α-lactalbumin as an active ingredient. More specifically, the present invention relates to various diseases caused by active oxygen, such as diseases caused by blood flow disorders (myocardial infarction, stroke, hypertension, menstrual pain, stiff shoulders, neuralgia, low back pain, hangover, etc.), adult diseases / internal medicine An active oxygen reducing agent that can be widely used for the treatment and improvement of diseases (cancer, nephritis, hepatitis, diabetes, etc.), beauty and skin diseases (stains, freckles, rough skin, coldness, constipation, wrinkles, atopic dermatitis, etc.) About.
活性酸素とは、スーパーオキサイドや過酸化水素、ヒドロキシラジカル、一重項酸素等を指し、安定な通常の酸素と異なり反応性に富んでいる。マクロファージは自ら活性酸素を生成し、異物を攻撃し排除している。しかし、過剰に産生した活性酸素は、正常細胞にも作用するので、生体に対して種々の障害も引き起こすことが知られている。例えば、脂質の過酸化による膜の損傷、タンパク質の酸化修飾によるタンパク質の構造変化、ＤＮＡの切断等の結果、細胞に障害作用を示し、様々な疾病の原因ともなることが明らかにされている。 Active oxygen refers to superoxide, hydrogen peroxide, hydroxy radical, singlet oxygen and the like, and is rich in reactivity unlike stable normal oxygen. Macrophages themselves generate active oxygen and attack and eliminate foreign substances. However, it is known that the excessively produced active oxygen also acts on normal cells and thus causes various damages to the living body. For example, as a result of damage to the membrane due to lipid peroxidation, structural change of the protein due to oxidative modification of the protein, cleavage of DNA, etc., it has been revealed that it has a damaging effect on cells and causes various diseases.
抗酸化作用を有する食品成分としては、β−ラクトグロブリンが知られているが、食品中の酸化防止用（特許文献１参照）であり、生体内の活性酸素を低減する作用を有しているかは不明である。
安全で且つ活性酸素低減作用（活性酸素濃度を減少させる作用のみならず、これに起因して生じると考えられる種々の病気の予防、改善の作用をも含む。）を有し、食品等に用いられるものがあれば、人の健康及び美容にとって非常に有用であり、その必要性は極めて大きい。近年のようにストレスが多く、それに起因する多くの病気が発生している状況においては特にその必要性が大きいことから、安全で且つ優れた活性酸素低減作用を有する製品の開発が強く望まれていた。
本発明は、上記現状に鑑みてなされたものであり、乳由来のα−ラクトアルブミンを原料として用い、生体内において安全で且つ優れた活性酸素低減剤を提供することを目的とする。
Safe and active oxygen reducing action (not only the action of reducing the active oxygen concentration, but also the action of preventing and ameliorating various diseases that may be caused by this), and used for food Anything that can be done is very useful for human health and beauty, and the need is extremely high. The development of a product that is safe and has an excellent action for reducing active oxygen is strongly desired, especially in the situation where there is a lot of stress as in recent years and many diseases resulting from it have occurred. It was.
The present invention has been made in view of the above situation, and an object of the present invention is to provide an active oxygen reducing agent that is safe and excellent in vivo using milk-derived α-lactalbumin as a raw material.
以上の観点より、本発明者等は、乳由来組成物に着目して種々検討したところ、α−ラクトアルブミンが、生体内において活性酸素低減作用を有することを明らかにし、本発明を完成するに至ったものである。 From the above viewpoints, the present inventors have made various studies focusing on milk-derived compositions. As a result, it has been clarified that α-lactalbumin has an action of reducing active oxygen in vivo, and the present invention is completed. It has come.
すなわち、本発明は、
（１）α−ラクトアルブミンを有効成分として含有してなる活性酸素低減剤、
（２）α−ラクトアルブミン含有量が５〜１０％である上記（１）に記載の活性酸素低減組成剤、
からなる。
That is, the present invention
(1) an active oxygen reducing agent comprising α-lactalbumin as an active ingredient,
(2) The active oxygen reducing composition according to the above (1), wherein the α-lactalbumin content is 5 to 10%,
Consists of.
本発明に係る組成物は、生体内における活性酸素低減作用に優れることから、活性酸素低減作用に起因する効果に有効である。従って、本発明に係る組成物は、活性酸素種が原因となる各種の病気、例えば、血流障害による病気（心筋梗塞、脳卒中、高血圧、生理痛、肩こり、神経痛、腰痛、二日酔い等）、成人病・内科疾患（癌、腎炎、肝炎、糖尿病等）、美容・皮膚病（しみ、そばかす、肌荒れ、冷え症、便秘、しわ、アトピー性皮膚炎等）等の治療、改善等に優れた効果を発揮するものと考えられる。
また、本発明に係る組成物に含まれるα−ラクトアルブミンは乳由来であることから、吸収効果に優れると共に、経口投与により簡易に摂取でき、有害な成分及び重金属は認められず安全である。
Since the composition according to the present invention is excellent in the active oxygen reducing action in a living body, it is effective for the effect resulting from the active oxygen reducing action. Therefore, the composition according to the present invention can be used for various diseases caused by reactive oxygen species, for example, diseases caused by impaired blood flow (myocardial infarction, stroke, hypertension, menstrual pain, stiff shoulders, neuralgia, low back pain, hangover, etc.), adults Excellent effect on treatment and improvement of diseases and medical diseases (cancer, nephritis, hepatitis, diabetes, etc.), beauty and skin diseases (stains, freckles, rough skin, coldness, constipation, wrinkles, atopic dermatitis, etc.) It is thought to do.
Moreover, since α-lactalbumin contained in the composition according to the present invention is derived from milk, it is excellent in absorption effect and can be easily ingested by oral administration, and no harmful components and heavy metals are recognized and is safe.
本発明は、α−ラクトアルブミンを有効成分とする活性酸素低減剤を提供する。本発明は、乳由来タンパク質の１つであるα−ラクトアルブミンにカタラーゼ活性増強作用を有することを見出したことに基づくものである。 The present invention provides an active oxygen reducing agent containing α-lactalbumin as an active ingredient. The present invention is based on the finding that α-lactalbumin, one of milk-derived proteins, has a catalase activity enhancing action.
したがって、本発明のα−ラクトアルブミンは、生体内において血清中の活性酸素低減作用を示す。該α−ラクトアルブミンは、食品に添加可能な濃度で過酸化脂質上昇抑制作用を示すので、食品、特に特定保健用食品、保健機能食品等の機能性食品に添加して過酸化脂質上昇抑制作用を有する食品を製造することができる。また、食品添加物としても使用可能であり、さらに、医薬品などにも添加することが可能である。 Therefore, α-lactalbumin of the present invention exhibits an action of reducing active oxygen in serum in vivo. The α-lactalbumin exhibits a lipid peroxide increase inhibitory action at a concentration that can be added to foods. Therefore, it is added to foods, particularly functional foods such as foods for specified health use and health functional foods, to suppress lipid peroxide increase. Can be produced. It can also be used as a food additive, and can also be added to pharmaceuticals.
α−ラクトアルブミンとは、乳の主要タンパク質で、乳汁中に少量（牛乳中に約0.5%）含まれるアルブミンである。本発明ではα−ラクトアルブミンを５〜１０％、さらに好ましくは９〜１０％用いることが望ましい。α−ラクトアルブミンは精製物を用いてもよいが、乳またはホエイに含まれているのでこれらをそのまま用いてもよいし、粗精製したものを用いても構わない。 α-Lactalbumin is a major protein of milk and is an albumin contained in a small amount in milk (about 0.5% in milk). In the present invention, α-lactalbumin is desirably used in an amount of 5 to 10%, more preferably 9 to 10%. α-Lactalbumin may be used as a purified product, but since it is contained in milk or whey, these may be used as they are, or a crude product may be used.
過酸化水素は、細胞内に浸透しやすく、そこで鉄や銅イオンと結びついてしまえば、たちまちハイドロキシラジカルという活性酸素に変身してしまう性格を持っている。また、スーパーオキサイドラジカルと反応することで、ハイドロキシラジカルや一重項酸素に変わったりもする。このように、毒性の高い化合物が過酸化水素である。
一方、カタラーゼは、過酸化水素を水と酸素に変換する生体内酵素で、酵素活性が低下すると、活性酸素が体内にたまり、疾病を誘発しやすくなる。
Hydrogen peroxide easily penetrates into cells, and if it is combined with iron or copper ions, it has the property of being transformed into active oxygen called a hydroxyl radical. Moreover, by reacting with a superoxide radical, it may be changed to a hydroxy radical or singlet oxygen. Thus, hydrogen peroxide is a highly toxic compound.
Catalase, on the other hand, is an in vivo enzyme that converts hydrogen peroxide into water and oxygen. When the enzyme activity decreases, active oxygen accumulates in the body, making it easier to induce disease.
α−ラクトアルブミンを製剤化して医薬品とする場合には、治療目的や投与経路等に応じて剤形を選択することができ、例えば、錠剤、丸剤、散剤、液剤、懸濁剤、乳剤、顆粒剤、カプセル剤、注射剤、坐剤、エリキシル剤、シロップ剤、浸剤、煎剤等が挙げられる。また製剤化のために、必要に応じて充填剤、増量剤、結合剤、保湿剤、崩壊剤、界面活性剤、滑沢剤等の希釈剤あるいは賦形剤を用いることができる。また、この医薬製剤中に着色剤、保存剤、香料、風味剤、甘味剤等や他の医薬品を医薬製剤中に含有させてもよい。 When α-lactalbumin is formulated into a pharmaceutical product, the dosage form can be selected according to the therapeutic purpose, administration route, etc., for example, tablets, pills, powders, solutions, suspensions, emulsions, Examples include granules, capsules, injections, suppositories, elixirs, syrups, soaking agents, and decoction. For formulation, diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and lubricants can be used as necessary. In addition, a colorant, a preservative, a fragrance, a flavoring agent, a sweetening agent, and other pharmaceuticals may be included in the pharmaceutical preparation.
α−ラクトアルブミンを含む食品の形態としては、健康食品、特定保健用食品、栄養補助食品、経腸栄養食品等を挙げることができる。α−ラクトアルブミンと食品衛生上許容される配合物、例えば、安定化剤、保存剤、着色料、香料、ビタミン等の配合物を上記α−ラクトアルブミンに適宜添加し、混合し、常法により、錠剤、粒状、顆粒状、粉末状、カプセル状、液状、クリーム状、飲料等の食品とすることができる。 Examples of the form of food containing α-lactalbumin include health food, food for specified health use, nutritional supplement, enteral nutrition food, and the like. Alpha-lactalbumin and food hygiene-acceptable blends, for example, stabilizers, preservatives, colorants, flavors, vitamins, etc. are added to the above-mentioned alpha-lactalbumin as appropriate, mixed, and in a conventional manner. , Tablets, granules, granules, powders, capsules, liquids, creams, beverages and the like.
以下、実施例により本発明を具体的に説明するが、本発明は、これら実施例に制限されるものではない。 EXAMPLES Hereinafter, although an Example demonstrates this invention concretely, this invention is not restrict | limited to these Examples.
[実施例１]
Wistar系雄ラット（３週齢）を１週間CE-2（日本クレア株式会社製、水分8.93%、粗タンパク質25.40%、粗脂肪4.43%、粗繊維4.13%、粗灰分6.93%、可溶性無窒素物50.18%）で飼育し、その後５日間は20%カゼイン標準食（20C、表１）を水道水と共に自由摂取させ予備飼育を行った。購入日から予備飼育９日目まで５室ケージで飼育し、10日目より代謝ケージに移した。
実験開始日（０日目）に各群の体重が等しくなるように３群（６頭／群）に分け、腎炎２群には、抗ラット糸球体基底膜ウサギ抗血清0.25mL/ratをWistar系雄ラットの尾静脈に注射し、糸球体腎炎を惹起させた。翌日（１日目）、ウサギγ−グロブリン(8mg/0.1mL生理食塩水/rat）：Freund's complete adjuvant=1:1のエマルジョンを後肢フットパッドに0.2mL/rat皮下注射した。実験０日目から各群共に実験食として、20Cおよび9%ラクトアルブミン食（9α-La、表１）をmiliQ水で固めたものを14日間自由摂取させた。20Cを摂取する正常群も設けた。実験開始14日目の午前９時に飼料を取り除き、水は与えたまま、午後１時に肝臓を採取した。
[Example 1]
Wistar male rats (3 weeks old) for 1 week CE-2 (manufactured by CLEA Japan, moisture 8.93%, crude protein 25.40%, crude fat 4.43%, crude fiber 4.13%, crude ash content 6.93%, soluble nitrogen-free substance 50.18%), and then, for 5 days, 20% casein standard diet (20C, Table 1) was freely ingested with tap water and preliminarily reared. The animals were reared in a five-chamber cage from the date of purchase to the 9th day of preliminary breeding, and transferred to the metabolic cage from day 10.
The group was divided into 3 groups (6 animals / group) so that the weight of each group would be equal on the start day of experiment (day 0), and anti-rat glomerular basement membrane rabbit antiserum 0.25 mL / rat was added to Wistar for 2 groups of nephritis. Injected into the tail vein of male male rats to induce glomerulonephritis. The next day (Day 1), rabbit γ-globulin (8 mg / 0.1 mL saline / rat): Freund's complete adjuvant = 1: 1 emulsion was subcutaneously injected into the hind leg footpad at 0.2 mL / rat. From day 0 of the experiment, each group was allowed to freely ingest a 20C and 9% lactalbumin diet (9α-La, Table 1) solidified with miliQ water as an experimental diet for 14 days. There was also a normal group taking 20C. At 9 am on the 14th day from the start of the experiment, the feed was removed, and the liver was collected at 1 pm with water.
[抗酸化酵素活性の測定]
ラット解剖時に、肝臓0．2gを精秤し、液体窒素で氷結させ、−84℃で保存した。試験管に0.1％TritonX-100-50mMリン酸緩衝液を5mL入れ、ポリトロンで氷冷下ホモジナイズした。続いて、超遠心用チューブに氷冷下0.1％TritonX-100-50mMリン酸緩衝液5mLで共洗いしながら移した後、19000×g、4℃、30分間超遠心した。上清をバイアルに分注し、測定まで冷凍保存した。
測定試料（酵素液）2mLに30mM H2O2-50mMリン酸緩衝液を1mLを加え、攪拌し240nmで吸光度の経時変化を測定した（15秒間）。対照は、酵素液2mLに50mMリン酸緩衝液を1mL加え、攪拌し240nmで吸光度を測定したものを用いた。
その結果、対照群に比べ、20C摂取群は腎炎によるカタラーゼ活性が低下するが、α−ラクトアルブミン摂取群は腎炎によるカタラーゼ活性低下を抑制するばかりでなく、対照群に比べても有意にカタラーゼ活性を上昇させることがわかった（図１）。
[Measurement of antioxidant enzyme activity]
At the time of rat dissection, 0.2 g of the liver was precisely weighed, frozen with liquid nitrogen, and stored at -84 ° C. 5 mL of 0.1% TritonX-100-50 mM phosphate buffer was added to the test tube, and homogenized with polytron under ice-cooling. Subsequently, the sample was transferred to an ultracentrifuge tube while being washed with 5 mL of 0.1% TritonX-100-50 mM phosphate buffer under ice cooling, and then ultracentrifuged at 19000 × g, 4 ° C. for 30 minutes. The supernatant was dispensed into vials and stored frozen until measurement.
1 mL of 30 mM H 2 O 2 -50 mM phosphate buffer was added to 2 mL of the measurement sample (enzyme solution), stirred, and the change with time in absorbance was measured at 240 nm (15 seconds). As a control, 1 mL of 50 mM phosphate buffer was added to 2 mL of enzyme solution, and the mixture was stirred and the absorbance was measured at 240 nm.
As a result, compared to the control group, the catalase activity due to nephritis decreased in the 20C intake group, but the α-lactalbumin intake group not only suppressed the decrease in catalase activity due to nephritis, but also significantly reduced the catalase activity compared to the control group. (Fig. 1).
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004043523A JP4578821B2 (en) | 2004-02-19 | 2004-02-19 | Pharmaceutical composition for the treatment of nephritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004043523A JP4578821B2 (en) | 2004-02-19 | 2004-02-19 | Pharmaceutical composition for the treatment of nephritis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005232085A true JP2005232085A (en) | 2005-09-02 |
| JP4578821B2 JP4578821B2 (en) | 2010-11-10 |
Family
ID=35015404
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004043523A Expired - Lifetime JP4578821B2 (en) | 2004-02-19 | 2004-02-19 | Pharmaceutical composition for the treatment of nephritis |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4578821B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013241418A (en) * | 2007-05-11 | 2013-12-05 | Meiji Co Ltd | New antiphlogistic-analgesic agent |
| WO2016163400A1 (en) * | 2015-04-07 | 2016-10-13 | 株式会社明治 | Hot flash-suppressing agent |
| JP2016204356A (en) * | 2015-04-23 | 2016-12-08 | 株式会社明治 | Hepatic fibrogenesis inhibitor |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05146797A (en) * | 1991-11-28 | 1993-06-15 | Meidensha Corp | Method for eliminating active oxygen in ozonization |
| JP2002275018A (en) * | 2001-03-14 | 2002-09-25 | Kose Corp | Skin care preparation |
-
2004
- 2004-02-19 JP JP2004043523A patent/JP4578821B2/en not_active Expired - Lifetime
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05146797A (en) * | 1991-11-28 | 1993-06-15 | Meidensha Corp | Method for eliminating active oxygen in ozonization |
| JP2002275018A (en) * | 2001-03-14 | 2002-09-25 | Kose Corp | Skin care preparation |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013241418A (en) * | 2007-05-11 | 2013-12-05 | Meiji Co Ltd | New antiphlogistic-analgesic agent |
| JP5683106B2 (en) * | 2007-05-11 | 2015-03-11 | 株式会社明治 | New anti-inflammatory analgesic |
| WO2016163400A1 (en) * | 2015-04-07 | 2016-10-13 | 株式会社明治 | Hot flash-suppressing agent |
| JP6038416B1 (en) * | 2015-04-07 | 2016-12-07 | 株式会社明治 | Fire suppression agent |
| US11147856B2 (en) | 2015-04-07 | 2021-10-19 | Meiji Co., Ltd. | Hot flash-suppressing agent |
| JP2016204356A (en) * | 2015-04-23 | 2016-12-08 | 株式会社明治 | Hepatic fibrogenesis inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4578821B2 (en) | 2010-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2428977C2 (en) | Leucine-enriched composition | |
| HU228847B1 (en) | Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability | |
| JP5242885B2 (en) | Intramuscular AMPK activator | |
| KR20200039748A (en) | Amino acid composition for treatment of liver disease | |
| TW200913988A (en) | Anti-fatigue agent and oral composition each comprising andrographolide as active ingredient | |
| WO2010041647A1 (en) | Physical endurance improving agent, anti-fatigue agent or fatigue recovering agent comprising amino acid composition as active ingredient | |
| JP5939550B2 (en) | Oxidized albumin lowering agent | |
| JP2007254440A (en) | Lipid metabolism-adjusting agent and lipid metabolism-adjusting food | |
| KR101695848B1 (en) | A composition comprising ginsenoside f2 for preventing or treating non-alcoholic liver disease | |
| JP2014129323A (en) | Inhibitor of fat accumulation in liver | |
| JP4520089B2 (en) | Rubrofusarin glycoside-containing composition | |
| KR100304312B1 (en) | Zinc Supplemented Prostate Extract | |
| JP2005232085A (en) | Active oxygen-reducing agent | |
| JP4974553B2 (en) | Acetaldehyde metabolism promoter | |
| US20090082269A1 (en) | Agent for ameliorating heavy metal-induced disorders, and medicinal composition, food and cosmetic containing the same | |
| WO2010110439A1 (en) | Composition for regulating autonomic nervous activity and method for regulating autonomic nerve | |
| JP5938219B2 (en) | Food or medical agent for delayed gastric emptying | |
| JP4163801B2 (en) | Alcohol metabolism promoting agent | |
| CN107427417A (en) | Chlorophyll composition | |
| JP6437183B2 (en) | Liver function improving agent | |
| US11684618B2 (en) | Compositions comprising mixtures of compounds and uses thereof | |
| JP2001026753A (en) | Composition for prophylaxis or treatment of hypertension | |
| TWI745609B (en) | Composition for promoting antioxidative activity | |
| TW201043154A (en) | Anti-mental fatigue agent | |
| WO2020029221A1 (en) | Composition with inhibiting fat formation and antioxidative activities and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060920 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091021 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091130 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100126 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20100402 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100426 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100526 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100526 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100720 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100824 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100825 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130903 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4578821 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130903 Year of fee payment: 3 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130903 Year of fee payment: 3 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |